Analyst Jeet Mukherjee from BTIG reiterated a Buy rating on Monopar Therapeutics Inc and increased the price target to $104.00 from $87.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jeet Mukherjee’s rating is based on the recent developments in Monopar Therapeutics Inc’s copper balance analysis for their drug ALXN1840, which is targeted at Wilson’s disease patients. The updated analysis, published in a reputable journal, highlights a consistent negative trend in copper balance among patients, suggesting that the previous calculations by AstraZeneca were flawed. This new data point strengthens Monopar’s position as they prepare for a New Drug Application with the FDA in early 2026.
Furthermore, the patient-by-patient data revealed that the majority of patients experienced a significant decrease in copper levels over the treatment period, reinforcing the drug’s efficacy. Although there remains some uncertainty regarding FDA approval, the overall trends and the drug’s benefit-risk profile support a positive outlook. Consequently, Mukherjee has increased the probability of success for ALXN1840, contributing to a higher price target and reaffirming the Buy rating for MNPR.
In another report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $109.00 price target.